Michael L Miller

Years Active: 2019-2020
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Jose F Ponte, Leanne Lanieri, Eshita Khera, Rassol Laleau, Olga Ab, Christopher Espelin, Neeraj Kohli, Bahar Matin, Yulius Setiady, Michael L Miller, Thomas A Keating, Ravi Chari, Jan Pinkas, Richard Gregory, Greg M Thurber
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy. Molecular cancer therapeutics 20 (1) (2020)
Rajeeva Singh, Emily E Reid, Luke Harris, Paulin L Salomon, Michael L Miller, Ravi V J Chari, Thomas A Keating
Antibody-Drug Conjugates with Indolinobenzodiazepine Dimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer Catabolites in Target Cancer Cells. Molecular pharmaceutics 17 (1) (2019)
Paulin L Salomon, Emily E Reid, Katie E Archer, Luke Harris, Erin K Maloney, Alan J Wilhelm, Michael L Miller, Ravi V J Chari, Thomas A Keating, Rajeeva Singh
Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Molecular pharmaceutics 16 (12) (2019)
Chen Bai, Emily E Reid, Alan Wilhelm, Manami Shizuka, Erin K Maloney, Rassol Laleau, Lauren Harvey, Katie E Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L Miller, Ravi Chari, Thomas A Keating, Nicholas C Yoder
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjugate chemistry 31 (1) (2019)

Michael L Miller.css-eqlu8i{font-size:small;padding-left:4px;}